Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.

ABSTRACT:

Background

Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our study intended to establish the association between overall survival and vaccine-induced T cell responses against tumor associated antigens (TAA) targeted by the vaccine.

Method

The TIME trial was a placebo-controlled, randomized phase II study aimed at assessing efficacy of TG4010 with chemotherapy in NSCLC. 78 patients from the TIME study carrying the HLA-A02*01 haplotype were analyzed using combinatorial encoding of MHC multimers to detect low frequencies of cellular immune response

SUBMITTER: Tosch C 

PROVIDER: S-EPMC5604422 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature